Clinical analysis of patients (pts) with Lung cancer treated with anti-PD1/PDL1 therapy.

被引：0
|
作者：
Tian, Kaihua
Wang, Xintong
机构：
[1] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China
[2] ChosenMed Technol Co Ltd, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20522
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical analysis of patients (pts) with lung cancer treated with anti-PD1/PDL1 therapy
    Zhao, Xin
    Liu, Siyao
    Su, Junyan
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [2] Anti-PD1/PDL1 induced psoriasis
    Voudouri, D.
    Nikolaou, V.
    Laschos, K.
    Charpidou, A.
    Soupos, N.
    Triantafyllopoulou, I.
    Panoutsopoulou, I.
    Tsimpoukis, S.
    Aravantinos, G.
    Syrigos, K.
    Stratigos, A. J.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 53 - 54
  • [3] Anti-PD1/PDL1 induced psoriasis
    Voudouri, Dimitra
    Nikolaou, Vasiliki
    Laschos, Konstantinos
    Charpidou, Andriani
    Soupos, Nikolaos
    Triantafyllopoulou, Ioanna
    Panoutsopoulou, Ioanna
    Aravantinos, Gerasimos
    Syrigos, K.
    Stratigos, A.
    [J]. CURRENT PROBLEMS IN CANCER, 2017, 41 (06) : 407 - 412
  • [4] Distribution of anti-PD1/PDL1 autoantibodies in multiple cancer types and potential biomarker role for anti-PD1 therapy
    Tan, Q.
    Wang, Y.
    Liu, S.
    Luo, R.
    Wang, S.
    Liang, T.
    Yang, J.
    Xing, P.
    Yao, J.
    Wu, D.
    Zhang, Z.
    Dai, J.
    Yu, X.
    Han, X.
    Shi, Y.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1097 - S1098
  • [5] Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
    Lei, Qingyang
    Wang, Dan
    Sun, Kai
    Wang, Liping
    Zhang, Yi
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [6] Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma.
    Eroglu, Zeynep
    Kim, Dae Won
    Johnson, Douglas Buckner
    Algazi, Alain Patrick
    Munhoz, Rodrigo Ramella
    Liniker, Elizabeth
    Kong, Ben
    Khurana, Neharika
    Chmielowski, Bartosz
    Sosman, Jeffrey Alan
    Scolyer, Richard A.
    Carlino, Matteo S.
    Postow, Michael Andrew
    Hwu, Wen-Jen
    Long, Georgina V.
    Ribas, Antoni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer
    Yin, Huanhuan
    Guo, Wei
    Sun, Xiangling
    Li, Ruili
    Feng, Cuihua
    Tan, Yujie
    [J]. JOURNAL OF IMMUNOLOGY RESEARCH, 2020, 2020
  • [8] Analysis of predictive and prognostic soluble biomarkers in advanced non-small cell lung cancer (NSCLC) patients treated with anti-PD1/PDL1
    Gallach Garcia, S.
    Garde Noguera, J.
    Torres Martinez, S.
    Aparisi Aparisi, F. D. A.
    Vidal Martinez, J.
    Escorihuela, E.
    Gisbert Criado, R.
    Moreno, A.
    Ferrero Gimeno, M.
    Meri Abad, M.
    Shaheen, I.
    Calabuig-Farinas, S.
    Blasco Cordellat, A.
    Honrubia Peris, B.
    Garcia Sanchez, J.
    Jantus Lewintre, E.
    Camps, C.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S714 - S714
  • [9] Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy
    Luo, Kunpeng
    Liu, Shuqiang
    Shen, Xiuyun
    Xu, Jincheng
    Shi, Chunpeng
    Chao, Yuqiu
    Wen, Zhengchao
    Zhang, Kejiao
    Wang, Ru
    Liu, Bing
    Jiang, Yanan
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [10] Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
    Weidhaas, Joanne
    Marco, Nicholas
    Scheffler, Aaron W.
    Kalbasi, Anusha
    Wilenius, Kirk
    Rietdorf, Emily
    Gill, Jaya
    Heilig, Mara
    Desler, Caroline
    Chin, Robert K.
    Kaprealian, Tania
    McCloskey, Susan
    Raldow, Ann
    Raja, Naga P.
    Kesari, Santosh
    Carrillo, Jose
    Drakaki, Alexandra
    Scholz, Mark
    Telesca, Donatello
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
12345